Baxter International

BAX Health Care Market cap $12.3B as of Sep 14, 2026 16:00 ET S&P 500

Q2 FY26 Apr 1 – Jun 30, 2026 reported Jul 30, 2026

Revenue$2.96B +5% year over year

Gross profit$1.03B 35% margin

Operating profit$0.22B 7% margin

Net profit$0.13B 4% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	2.96	100%	+5%
US	1.60	54%	+4%
Non US	1.37	46%
Cost of revenue	−1.93	65%
Gross profit	1.03	35% margin	+0pp
R&D	−0.13	5%	+0pp
SG&A	−0.69	23%	−1pp
Operating profit	0.22	7% margin	+1pp
Interest & other costs	−0.07
Tax	−0.02
Net profit	0.13	4% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	2.70	100%	+3%
US	1.44	53%	−4%
Non US	1.27	47%	+12%
Cost of revenue	−1.81	67%
Gross profit	0.89	33% margin	+0pp
R&D	−0.14	5%	+0pp
SG&A	−0.69	26%	+0pp
Operating profit	0.07	2% margin	+0pp
Interest & other costs	−0.08
Net profit	−0.02	−1% margin	−5pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	2.97	100%	+8%
US	1.55	52%	+3%
Western Europe Canada Japan	1.02	35%	+15%
Eastern Europe Middle	0.40	13%	+14%
Cost of revenue	−2.40	81%
Gross profit	0.58	19% margin	−15pp
R&D	−0.13	4%	+0pp
SG&A	−0.76	26%	+0pp
Other	−0.42	14%	+0pp
Operating profit	−0.73	−25% margin	+0pp
Interest & other costs	−0.12
Tax	−0.28
Net profit	−1.13	−38% margin	−19pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	2.84	100%	+5%
US	1.54	54%	+3%
Western Europe Canada Japan	0.94	33%	+10%
Eastern Europe Middle	0.36	13%	+2%
Cost of revenue	−1.89	66%
Gross profit	0.95	34% margin	−5pp
R&D	−0.12	4%	−1pp
SG&A	−0.66	23%	−3pp
Operating profit	0.17	6% margin	+0pp
Interest & other costs	−0.05
Tax	−0.17
Net profit	−0.05	−2% margin	−7pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	2.81	100%	+4%
US	1.54	55%	+3%
Western Europe Canada Japan	0.93	33%	+9%
Eastern Europe Middle	0.34	12%	−1%
Cost of revenue	−1.82	65%
Gross profit	0.99	35% margin	−3pp
R&D	−0.13	5%	+0pp
SG&A	−0.67	23%	−1pp
Operating profit	0.19	7% margin	+0pp
Interest & other costs	−0.10
Net profit	0.09	3% margin	+15pp

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 1 – Jun 30, 2026 reported Jul 30, 2026 Operating margin 7% Net profit $0.13B	Apr 1 – Jun 30, 2026	Jul 30, 2026	$2.96B	+5%	7%	$0.13B	4%
Q1 FY26 Jan 1 – Mar 31, 2026 reported Apr 30, 2026 Operating margin 2% Net profit −$0.02B	Jan 1 – Mar 31, 2026	Apr 30, 2026	$2.70B	+3%	2%	−$0.02B	−1%
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 12, 2026 Operating margin −25% Net profit −$1.13B	Oct 1 – Dec 31, 2025	Feb 12, 2026	$2.97B	+8%	−25%	−$1.13B	−38%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Nov 4, 2025 Operating margin 6% Net profit −$0.05B	Jul 1 – Sep 30, 2025	Nov 4, 2025	$2.84B	+5%	6%	−$0.05B	−2%
Q2 FY25 Apr 1 – Jun 30, 2025 reported Aug 5, 2025 Operating margin 7% Net profit $0.09B	Apr 1 – Jun 30, 2025	Aug 5, 2025	$2.81B	+4%	7%	$0.09B	3%